Zohar Yahalom


A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | R | S | T | V | W | Y | Z
+972 3 692 5993
+972 3 696 6464


Zohar Yahalom heads the Health Technologies and Life Sciences Regulation Department. Until 2000, Zohar served as the Legal Advisor to the Medical Technologies Administration and the Pharmaceutical Division at The Israeli Ministry of Health and as a Special Advisor to the Director-General of the Ministry of Health.

As a member of several national committees on major healthcare policy issues (parallel import of pharmaceuticals, regulation of drug maximum prices, regulation of herbal medicines, regulation of the pharmacy profession and the reform in the OTC market), Zohar was personally involved in most of the major reforms affecting the Israeli regulation of the pharmaceutical market to date. Zohar is a well-known expert on the regulation of the Israeli healthcare system and pharmaceutical market and is the author of numerous books and articles on regulatory. He is also a lecturer in academic and professional forums.

Prior to joining HFN in 2016, Zohar headed a boutique law firm with a dedicated practice advising pharmaceutical, biotech and medical device companies involved in the Israeli market, as well as healthcare providers.

Zohar represented various companies and organizations in administrative proceedings before the High Court of Justice and the Courts of Administrative Affairs and has reached significant achievements in pre-court litigation before the regulatory authorities. Zohar was recognised as a leading expert on Life Sciences' Regulatory Affairs on Who's Who Legal for 2016 and his office was selected as one of the leading healthcare law firms in Israel in BDI's ranking for 2015 and 2016.

Zohar's comprehensive familiarity with the relevant markets enables him to offer his client services which are more than mere legal advising. Zohar has been involved in consolidating business strategies of pharmaceutical and medical products companies in regulation-related issues, including the mode of incorporation in Israel, campaigns for the inclusion of drugs in the National List of Reimbursed Drugs and dealing with generic competition.



  • Hebrew University, Jerusalem, Israel, LL.B, 1996; Dean's List (1994)

Admitted to Practice